Evidence map›Paper›PMID 41659642›Full record

ArticlebioRxiv : the preprint server for biology2026

A small molecule PTER-selective inhibitor reduces food intake and body weight.

Sipei Fu, Lushun Wang, Veronica L Li, Xuchao Lyu, Wei Wei, Xu Shi, Shuliang Deng, Jacob L Barber, Usman A Tahir, Charleen Adams and 14 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Sipei FuDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Lushun WangSarafan ChEM-H, Stanford University, Stanford, CA, USA.
Veronica L LiDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Xuchao LyuDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Wei WeiDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Xu ShiDivision of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Shuliang DengDivision of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Jacob L BarberDivision of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Usman A TahirDivision of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Charleen AdamsDivision of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
April CarsonDepartment of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Bertha HidalgoDepartment of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Laura M RaffieldDepartment of Genetics, University of North Carolina, Chapel Hill, NC, USA.ORCID 0000-0002-7892-193X
James G WilsonDivision of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Hlib RazumkovDepartment of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.
Shuke XiaoDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Jan SpaasDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
Daniel FernandezSarafan ChEM-H, Stanford University, Stanford, CA, USA.
Tinghu ZhangSarafan ChEM-H, Stanford University, Stanford, CA, USA.
Robert E GersztenDivision of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Mark D BensonDivision of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Nathanael S GraySarafan ChEM-H, Stanford University, Stanford, CA, USA.
Stephen M HinshawSarafan ChEM-H, Stanford University, Stanford, CA, USA.ORCID 0000-0003-4215-5206
Jonathan Z LongDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.

Funding

Chemical control of energy metabolism by N-acyl amino acidsR01DK124265 · NIDDK · STANFORD UNIVERSITY · PI LONG, JONATHAN Z · 2020 to 2024
$2.0M
CYP4F Enzymes Regulate N-Acyl Amino Acid Signaling in HumansR01DK137983 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Mark Daniel Benson · 2025 to 2026
$1.5M
NIDDK NIH HHS R01 DK124265NIDDK NIH HHS R01 DK137983
6 · The paper itself

Abstract

PTER (phosphotriesterase-related) is an amidohydrolase that mediates catabolism of the anorexigenic taurine metabolite N-acetyltaurine. However, the structural basis of PTER ligand binding and catalysis remain unknown, limiting our ability to harness this pathway therapeutically. Here we solve crystal structures of a eukaryotic PTER in apo and product-bound forms. These structures uncover an unexpected pocket homology between PTER and histone deacetylase (HDAC) enzymes. We exploit this similarity to engineer a first-in-class substrate-competitive PTER inhibitor called PTERi with nanomolar potency and >100-fold selectivity for PTER over HDACs in vitro. Administration of PTERi to diet-induced obese mice reduces feeding, enhances GLP1-RA (glucagon like peptide 1 receptor agonist)-induced weight loss, and prevents weight regain after GLP1-RA discontinuation. The structure of PTER connects histone and metabolite deacetylation into a parallel conceptual framework and enables proof-of-concept data for pharmacological inhibition of PTER in obesity.

Identifiers

PMID41659642
PMCPMC12873775

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.